Literature DB >> 23233598

Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Ralph M Meyer1, Richard T Hoppe.   

Abstract

The results of recent clinical trials for the management of limited-stage Hodgkin lymphoma have led to considerable debate, especially regarding the role of radiation therapy. This review highlights those recent trials and provides perspectives regarding their interpretation from a radiation oncologist and a hematologist. The trial protocol is available at http://www.nejm.org/doi/suppl/10.1056/NEJMoa1111961/suppl_file/nejmoa1111961_protocol.pdf.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233598     DOI: 10.1182/asheducation-2012.1.313

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  1 in total

1.  A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.

Authors:  Eric Van Den Neste; Marc André; Thomas Gastinne; Aspasia Stamatoullas; Corinne Haioun; Amine Belhabri; Oumedaly Reman; Olivier Casasnovas; Hervé Ghesquieres; Gregor Verhoef; Marie-José Claessen; Hélène A Poirel; Marie-Christine Copin; Romain Dubois; Peter Vandenberghe; Ioanna-Andrea Stoian; Anne S Cottereau; Sarah Bailly; Laurent Knoops; Franck Morschhauser
Journal:  Haematologica       Date:  2018-01-19       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.